We are pleased to have taken a significant step in the development of improved therapeutic options in ulcerative colitis treatment.

We believe that BGP345A has potential to provide a novel and effective approach to restoring gut motility where treatment is currently suboptimal. The initiation of patient enrolment is an important step in our development and confirms our commitment to develop novel live-microbial based solutions in areas of medical need.